NCT06090864View on ClinicalTrials.gov

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 25, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2031

Conditions
Hodgkin LymphomaRelapseRefractory
Interventions
DRUG

Chemotherapy

Subjects will receive a lymphodepletion regimen of bendamustine 70 mg/m2 IV and fludarabine 30 mg/m2 each as a daily infusion for 3 consecutive days prior to the ATLCAR.CD30.CCR4 cell infusion.

BIOLOGICAL

Cell infusion

ATLCAR.CD30.CCR4 cells infusion for the eligible subjects after depletion chemotherapy.

Trial Locations (1)

27599

RECRUITING

Lineberger Comprehensive Cancer Center, Chapel Hill

All Listed Sponsors
lead

UNC Lineberger Comprehensive Cancer Center

OTHER